Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment. (Q51095876)
Jump to navigation
Jump to search
scientific article published on 7 March 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment. |
scientific article published on 7 March 2017 |
Statements
Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment. (English)
1 reference
Kumiko Hamano
1 reference
Hiroshi Nishiyama
1 reference
Akiko Matsui
1 reference
Manaka Sato
1 reference
Masakazu Takeuchi
1 reference
7 March 2017
1 reference
64
1 reference
4
1 reference
449-456
1 reference